<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00217503</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000441214</org_study_id>
    <secondary_id>NCI-05-C-0203</secondary_id>
    <secondary_id>NCI-P6330</secondary_id>
    <nct_id>NCT00217503</nct_id>
    <nct_alias>NCT00121576</nct_alias>
  </id_info>
  <brief_title>Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma</brief_title>
  <official_title>Primary Effusion Lymphoma: A Pilot Trial of Bevacizumab and Modified Dose-Adjusted Infusional CDE Chemotherapy Preceded by a Brief Pre-Phase Assessment of Targeted Oncolytic Virotherapy With Bortezomib, Zidovudine and Valganciclovir</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Herpesvirus is found in the cancer cells of patients with primary effusion&#xD;
      lymphoma. Antiviral drugs, such as zidovudine and valganciclovir, may be able to act against&#xD;
      the herpesvirus in the cancer cells to help kill the cancer cells. Bortezomib may help the&#xD;
      antiviral drugs kill the cancer cells. Draining the effusion removes fluid that has built up.&#xD;
      Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some&#xD;
      block the ability of cancer cells to grow and spread. Others find cancer cells and help kill&#xD;
      them or carry cancer-killing substances to them. Bevacizumab may also stop the growth of&#xD;
      cancer cells by blocking blood flow to the cancer. Drugs used in chemotherapy, such as&#xD;
      cyclophosphamide, doxorubicin, and etoposide, work in different ways to stop the growth of&#xD;
      cancer cells, either by killing the cells or by stopping them from dividing. Giving&#xD;
      bortezomib together with antiviral therapy followed by effusion drainage, bevacizumab, and&#xD;
      combination chemotherapy may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving bortezomib together with antiviral&#xD;
      therapy followed by effusion drainage, bevacizumab, and combination chemotherapy works in&#xD;
      treating patients with primary effusion lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the complete response rate in patients with previously untreated primary&#xD;
           effusion lymphoma treated with effusion drainage and bevacizumab in combination with&#xD;
           chemotherapy comprising cyclophosphamide, doxorubicin, and etoposide.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the overall survival, disease-free survival, and progression-free survival of&#xD;
           patients treated with this regimen.&#xD;
&#xD;
        -  Determine the toxicity of this regimen in previously treated or untreated patients.&#xD;
&#xD;
        -  Determine, preliminarily, the biologic effects of targeted oncolytic virotherapy&#xD;
           comprising bortezomib, zidovudine, and valganciclovir in these patients.&#xD;
&#xD;
      OUTLINE: This is a 2-part, pilot study.&#xD;
&#xD;
      Patients who are HIV-positive receive highly-active antiretroviral therapy during study&#xD;
      treatment.&#xD;
&#xD;
        -  Part 1 (targeted oncolytic virotherapy)*: Patients receive bortezomib IV over 3-5&#xD;
           seconds on days 1, 4, and 8, zidovudine IV over 1 hour twice daily on days 1-10, and&#xD;
           oral valganciclovir (or ganciclovir IV) twice daily on days 1-14. One day after&#xD;
           completion of zidovudine, patients begin treatment in part 2.&#xD;
&#xD;
      NOTE: *Part 1 treatment may be omitted in patients who are acutely ill with primary effusion&#xD;
      lymphoma at study entry AND a 10- to 14-day delay of starting part 2 treatment may pose a&#xD;
      hazard to the patient.&#xD;
&#xD;
        -  Part 2&#xD;
&#xD;
             -  Effusion drainage: Patients undergo effusion drainage prior to each course of&#xD;
                bevacizumab* and chemotherapy. The drainage tube may remain in place to allow for&#xD;
                continuous drainage of effusion during treatment with bevacizumab* and&#xD;
                chemotherapy.&#xD;
&#xD;
             -  Bevacizumab* plus cyclophosphamide, doxorubicin, and etoposide (iCDE): Patients&#xD;
                receive bevacizumab* IV over 30-90 minutes on days 1 and 6, cyclophosphamide,&#xD;
                doxorubicin, and etoposide IV continuously over 96 hours beginning on day 1 and&#xD;
                continuing until day 5, and filgrastim (G-CSF) subcutaneously (SC) daily beginning&#xD;
                on day 6 and continuing until day 19 or until blood counts recover OR pegfilgrastim&#xD;
                SC on day 6.&#xD;
&#xD;
      NOTE: *Patients may receive iCDE without bevacizumab if they meet any exclusion criteria for&#xD;
      receiving bevacizumab.&#xD;
&#xD;
      Treatment with bevacizumab and iCDE repeats every 21 days for 4-8 courses in the absence of&#xD;
      disease progression or unacceptable toxicity. Patients achieving complete response (CR)&#xD;
      receive 2 additional courses beyond CR.&#xD;
&#xD;
      After completion of study treatment, patients are followed monthly for 6 months, every 2&#xD;
      months for 6 months, every 3 months for 1 year, every 6 months for 3 years, and then annually&#xD;
      thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 15 patients will be accrued for this study within 2.5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Response to therapy as measured by overall, disease-free, and progression-free survival each month</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effects of high-dose zidovudine and ganciclovir on tumor cells measured by various assays after 2 weeks of study treatment</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pegfilgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ganciclovir</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valganciclovir</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zidovudine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed primary effusion lymphoma (PEL) involving a body cavity&#xD;
&#xD;
               -  Kaposi's sarcoma associated-herpesvirus&#xD;
&#xD;
               -  Any anatomic site or distribution of involvement allowed&#xD;
&#xD;
               -  HIV infection allowed&#xD;
&#xD;
          -  Previously treated or untreated disease&#xD;
&#xD;
          -  No mass lesions in the brain (for patients receiving bevacizumab during study&#xD;
             treatment)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-3* NOTE: *ECOG 4 allowed if due to a mechanical effect of the PEL that can be&#xD;
             corrected by effusion drainage resulting in improved performance status to ECOG 3 or&#xD;
             better&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,000/mm^3&#xD;
&#xD;
          -  Platelet count &gt; 75,000/mm^3&#xD;
&#xD;
          -  No active bleeding or coagulopathy (for patients receiving bevacizumab during study&#xD;
             treatment)&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST and ALT &lt; 3 times upper limit of normal (ULN) (6 times ULN if due to&#xD;
             hyperalimentation)&#xD;
&#xD;
          -  Bilirubin &lt; 2.0 mg/dL OR&#xD;
&#xD;
          -  Total bilirubin ≤ 4.5 mg/dL AND direct bilirubin &lt; 0.4 mg/dL (for patients with&#xD;
             Gilbert's syndrome or receiving protease-inhibitor therapy)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance &gt; 50 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Patients receiving bevacizumab during study treatment must meet the following&#xD;
             criteria:&#xD;
&#xD;
               -  No deep venous or arterial thrombosis within the past 6 months&#xD;
&#xD;
               -  No uncontrolled hypertension (i.e., systolic blood pressure [BP] &gt; 160 mm Hg or&#xD;
                  diastolic BP &gt; 95 mm Hg)&#xD;
&#xD;
               -  No unstable angina&#xD;
&#xD;
               -  No New York Heart Association class II-IV congestive heart failure&#xD;
&#xD;
               -  No cardiac arrhythmia requiring medication&#xD;
&#xD;
               -  No clinically significant peripheral artery disease&#xD;
&#xD;
               -  No peripheral vascular disease ≥ grade 2&#xD;
&#xD;
               -  No prior myocardial infarction&#xD;
&#xD;
               -  No transient ischemic attack or cerebral vascular accident within the past 6&#xD;
                  months&#xD;
&#xD;
               -  No other clinically significant cardiovascular disease&#xD;
&#xD;
        Neurologic&#xD;
&#xD;
          -  Patients receiving bevacizumab during study treatment must meet the following&#xD;
             criteria:&#xD;
&#xD;
               -  No uncontrolled seizure disorder&#xD;
&#xD;
               -  No CNS bleeding within the past 6 months&#xD;
&#xD;
               -  No other substantial CNS disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other malignancy requiring treatment that would preclude study treatment,&#xD;
             including, but not limited to, any of the following:&#xD;
&#xD;
               -  Life-threatening Kaposi's sarcoma&#xD;
&#xD;
               -  Non-resectable lung cancer&#xD;
&#xD;
               -  Acute leukemia&#xD;
&#xD;
          -  No grade IV organ dysfunction unrelated to PEL&#xD;
&#xD;
          -  No infection requiring chronic systemic therapy that would preclude study treatment&#xD;
             (except HIV, hepatitis B, or hepatitis C), including, but not limited to, any of the&#xD;
             following:&#xD;
&#xD;
               -  Invasive aspergillosis&#xD;
&#xD;
               -  End-organ cytomegalovirus (CMV)&#xD;
&#xD;
                    -  CMV retinitis (e.g., ocular implants not requiring systemic therapy) allowed&#xD;
                       if controlled with local therapy&#xD;
&#xD;
          -  No other condition or circumstance that would preclude study participation&#xD;
&#xD;
          -  No gastrointestinal bleeding within the past 6 months (for patients receiving&#xD;
             bevacizumab during study treatment)&#xD;
&#xD;
          -  No pathological condition that would confer a high risk for bleeding (for patients&#xD;
             receiving bevacizumab during study treatment)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No live virus vaccines (e.g., vaccinia or rotavirus) or bacterial vaccines during and&#xD;
             for 3 months after completion of study treatment&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior cumulative anthracycline dose &gt; 450 mg/m^2 (unless cardiac ejection fraction&#xD;
             normal)&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No concurrent chronic daily aspirin ≥ 325 mg/day or nonsteroidal medication that&#xD;
             interferes with platelet function (for patients receiving bevacizumab during study&#xD;
             treatment)&#xD;
&#xD;
          -  No concurrent therapeutic anticoagulation (INR &gt; 1.5) unless patient is on full-dose&#xD;
             warfarin (for patients receiving bevacizumab during study treatment)&#xD;
&#xD;
               -  Full-dose anticoagulants allowed provided both of the following criteria are met:&#xD;
&#xD;
                    -  INR normal&#xD;
&#xD;
                    -  On a stable dose of warfarin or low-molecular weight heparin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard F. Little, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCI - HIV and AIDS Malignancy Branch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2007</verification_date>
  <study_first_submitted>September 20, 2005</study_first_submitted>
  <study_first_submitted_qc>September 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>June 18, 2013</last_update_submitted>
  <last_update_submitted_qc>June 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2013</last_update_posted>
  <keyword>AIDS-related peripheral/systemic lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Primary Effusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Valganciclovir</mesh_term>
    <mesh_term>Ganciclovir</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

